SLN Silence Therapeutics Plc

TIDMSLN

RNS Number : 8420J

Silence Therapeutics PLC

03 July 2017

Change of Adviser

3 July 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces the appointment of Peel Hunt LLP as its Nominated Adviser and Broker with immediate effect.

Enquiries:

 
 Silence Therapeutics plc                  Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive Officer    3457 6900 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser          Tel: +44 (0)20 
  and Broker)                               7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                          Tel: +44 (0) 
  FTI Consulting                            20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPFMGGNNZLGNZM

(END) Dow Jones Newswires

July 03, 2017 02:00 ET (06:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024